Neuropilin-1 receptor (NRP1) inhibition with a novel peptidomimetic agent, MR438, was evaluated with radiotherapy in medulloblastoma models in vitro on cancer stem-like cells as well as in vivo on heterotopic and orthotopic xenografts.
[Cancer Cell International]